Stemline Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. In December 2018, the FDA approved ELZONRIS, a targeted therapy directed to CD123, for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In November 2018, the European Medicines Agency (EMA) granted accelerated assessment to the marketing authorization application (MAA) of ELZONRIS in patients with BPDCN, which was submitted to the EMA in January 2019. ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and others. Other Stemline clinical candidates include SL-801, a novel oral small molecule reversible inhibitor of XPO1, which is currently in a Phase 1 trial of patients with advanced solid tumors and recent data was presented at the European Society of Medical Oncology (ESMO) annual conference; and SL-701, an immunotherapeutic which has completed a Phase 2 trial in patients with second-line glioblastoma and recent data were presented at the Society for Neuro-Oncology (SNO) annual conference.
Stemline Therapeutics can be found under the symbol STML.
Stemline’s initial public offering occurred on January 28, 2013.
Stemline is incorporated in the state of Delaware.
Stemline's corporate headquarters is located at the following address:
750 Lexington Avenue, 11th Floor
New York, NY 10022
Stemline does not pay a dividend at this time.
Stemline’s transfer agent is:
Computershare Trust Company, N.A.
P.O. Box 43078
Providence, RI 02940
1-800-962-4284 (from the United States, Canada, Puerto Rico)
1-781-575-3120 (non-United States)
Stemline’s fiscal year ends on December 31.